Alexion Pharmaceuticals: A Buying Opportunity?

Bernstein’s Geoffrey Porges and Vincent Chen think problems with Alexion Pharmaceuticals’ (ALXN) Kanuma are “resolvable.” They explain why: munish sharma/Reuters This morning, Alexion announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription and Drug User Fee Act (PDUFA) date… In their press release, Alexion noted that the delay was due to […]